TNFRSF4 antibody (PE)

Catalog No. ABIN7457089

The Mouse Monoclonal anti-TNFRSF4 antibody is suitable to detect TNFRSF4 in samples from Human. It has been validated for FACS.

Quick Overview for TNFRSF4 antibody (PE) (ABIN7457089)

Target: TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFRSF4 antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Clone: Ber-ACT35

Product Details anti-TNFRSF4 Antibody (PE)

Isotype: IgG1, kappa

Application Details

Application Notes: The amount of the reagent is suggested to be used 5 µL of antibody per test (million cells in 100 µL staining volume or per 100 µL of whole blood). Check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.

Comment:

Matching Isotype Control: PE Mouse IgG1, κ Isotype Control (ABIN7469761)

Restrictions: For Research Use only

Handling

Buffer: PBS with 0.05 % Proclin300, 1 % BSA

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2~8°C and protected from prolonged exposure to light. Do not freeze.

Target Details for TNFRSF4

Target: TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))

Alternative Name: CD134

Background: TXGP1L,TNFRSF4,ACT35 antigen,OX40L receptor,CD134,CD134, also known as OX40 and TNFRSF4, is a 50 kD type I transmembrane glycoprotein. It is a member of the TNF receptor family. OX40 is expressed on activated T lymphocytes including Th1, Th2, Th17, and Treg cells. The interaction of OX40 with OX40L results in B cell proliferation and antibody secretion, regulation of primary T cell expansion, and T cell survival. OX40 influences the size of the T cell memory pool and regulation of CD4+ T cell tolerance.

Gene ID: 7293

UniProt: P43489

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints